Peptide · Fact sheet

Plecanatide

Also known as Trulance · uroguanylin analog

Plecanatide is FDA approved as Trulance for adults with chronic idiopathic constipation or irritable bowel syndrome with constipation. It is not approved for general gut health, detoxification, inflammation, or tissue repair.

FDA approved for specific usesStrong human evidence for approved uses

What is Plecanatide?

Plecanatide is a 16-amino-acid analog of uroguanylin that activates guanylate cyclase-C on the intestinal surface.

Like linaclotide, it is minimally absorbed and its evidence is tied to local bowel and abdominal-symptom outcomes.

Benefits & claims

It offers a second approved peptide approach to gut-surface guanylate cyclase-C signaling.

Comparing it with linaclotide illustrates why related mechanisms still require product-specific efficacy and safety evidence.

What the evidence supports

  • Controlled trials found higher composite response rates than placebo for IBS-C and chronic idiopathic constipation.
  • Benefits are averages in defined trial populations and do not imply response for every person with constipation.
Research areas
  • Chronic idiopathic constipation
  • IBS with constipation
  • Abdominal pain and bloating
  • Bowel-frequency outcomes
  • Additional analyses of symptom response within the approved adult populations

Dosage & frequency

Product-specific label information

Trulance has a once-daily adult regimen for chronic idiopathic constipation and IBS-C.

Trulance

Adults with chronic idiopathic constipation or IBS-C

Amount
3 mg
Frequency
Once daily
Route studied or labeled
Oral

With or without food; pediatric restrictions and obstruction contraindication apply.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • The oral tablet acts through guanylate cyclase-C in the intestinal lumen.

Interactions & precautions

  • The label describes low interaction potential in vitro; these findings do not establish clinical safety for every combination.

What is still unresolved

  • The adult regimen is not established for pediatric treatment; the label has pediatric restrictions.

Side effects & risks

  • The label carries a boxed warning about serious dehydration in young pediatric patients and is not approved for pediatric use.
  • Diarrhea is the most common adverse reaction and can be severe.
  • It is contraindicated when mechanical gastrointestinal obstruction is known or suspected.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Strong human evidence for approved uses

Multiple Phase 3 trials support the adult constipation indications. Evidence does not extend to children, unrelated digestive conditions, or broad gut-wellness claims.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Pain: reported experiences

Positive account · personal report

Less constipation and cramping

A separate commenter described relief from constipation and painful cramping while also using a probiotic and pantoprazole.

Reported use in this account

Product
Trulance
Amount
Not specified clearly
Frequency
At night; exact frequency not stated
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: A live probiotic; Pantoprazole

Concurrent treatments, diagnosis and symptom changes were not independently checked.

Read the original account
Mixed account · personal report

Delayed bowel movements after colon surgery

A person with prior sigmoid-colon surgery described bowel movements eventually occurring after Trulance, with considerable pain during the wait and relief afterwards. They were also using other laxatives.

Reported use in this account

Product
Trulance
Amount
3 mg
Frequency
Not specified clearly
Route
Oral, taken with water
Duration
Three weeks at the report

Other exposures described: Polyethylene glycol; Other laxatives used during follow-up; Prior sigmoid-colon resection

Altered bowel anatomy and concurrent laxatives limit attribution. Later urgent-care discussion offered a different explanation for the pain; the author's electrolyte theory was not confirmed.

Read the original account

Approval status

Trulance is FDA approved for adults with chronic idiopathic constipation and adults with irritable bowel syndrome with constipation.

Approved uses

  • Chronic idiopathic constipation and IBS with constipation in adults under the Trulance label

FDA approved for adult constipation indications

Plecanatide is approved under the Trulance label for chronic idiopathic constipation and IBS with constipation in adults.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term head-to-head effectiveness versus linaclotide and other approved options
  • Reliable predictors of response and severe diarrhea
  • Safety and effectiveness outside the approved adult populations
  • Whether exploratory symptom composites translate into meaningful daily-life improvement

Summary

Trulance is approved for two adult constipation disorders, not general gut health or tissue repair.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA prescribing information: Trulance

    Approved adult indications, boxed warning, contraindications, and adverse reactions.

  2. pubmedIntegrated analysis of two Phase 3 IBS-C trials

    Controlled adult evidence for composite and individual symptom outcomes.

  3. pubmedPooled Phase 3 analysis in older adults

    Subgroup analysis illustrating efficacy, safety, and limitations in older participants.

How we assess sources · Suggest a correction